Akums Drugs and Pharmaceuticals Limited (NSE: AKUMS) and Windlas Biotech Ltd (NSE: WINDLAS) are both listed in the Domestic contract manufacturers industry. Akums Drugs and Pharmaceuticals has a market capitalisation of ₹11,225 Cr and Windlas Biotech ₹1,877 Cr, as of 9 Nov 2026. Their P/E ratios are 44 and 29.2 respectively. Return on equity is 8.02% for Akums Drugs and Pharmaceuticals and 12.23% for Windlas Biotech. Over one year, Akums Drugs and Pharmaceuticals's share price is up 66.0% and Windlas Biotech's is up 1.4%.
| Metric | Akums Drugs and Pharmaceuticals | Windlas Biotech |
|---|---|---|
| NSE Symbol | AKUMS | WINDLAS |
| BSE Code | 544222 | 543329 |
| Share Price | ₹765.00 | ₹972.00 |
| Market Cap | ₹11,225 Cr | ₹1,877 Cr |
| P/E Ratio | 44 | 29.2 |
| Return on Equity | 8.02% | 12.23% |
| Return on Assets | 4.84% | 5.55% |
| Dividend Yield | 0.14% | 0.69% |
| Beta (1Y) | 0.33 | 0.37 |
| 1-Year Price Change | +66.0% | +1.4% |
| 3-Month Price Change | +4.8% | +15.8% |
| 52-Week Range | ₹409.30 – ₹838.80 | ₹697.40 – ₹1,181.90 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹1,342 Cr | ₹264 Cr |
| Quarterly Net Profit | ₹115 Cr | ₹18 Cr |
| Net Margin | 8.5% | 6.8% |
| EPS (Basic, Quarter) | ₹7.37 | ₹8.75 |
| Results Basis | consolidated | standalone |
| Headquarters | Delhi | Dehradun, Uttarakhand |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. The company provides drugs, ayurvedic, nutraceuticals, food and dietary supplements, derma and cosmetics, healthcare and hospital products, over-the-counter (OTC) products, active pharmaceutical ingredients, excipients, and compounds. It also offers branded formulations on various dosage forms, including tablets, hard and soft gelatin capsules, liquid orals, sachets, vials, ampoules, form-fill-seal products, topical preparations, eye drops, dry…
Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. The company offers contract manufacturing; customized formulations; contract research and manufacturing services; customized formulation; and regulatory services. It also manufactures tablets, capsules, oral solids, modified-release formulations, chewable and dispersible tablets, customized generics, and complex generics and multi-drug combinations, as well as injectables, including liquid vials, lyophilized vials, and ampoules. In addition, the company o…
Akums Drugs and Pharmaceuticals has a market capitalisation of ₹11,225 Cr, against ₹1,877 Cr for Windlas Biotech as of 9 Nov 2026, about 6.0 times the size by market cap.
Akums Drugs and Pharmaceuticals has a P/E of 44 and Windlas Biotech a P/E of 29.2 as of 9 Nov 2026.
Akums Drugs and Pharmaceuticals has a return on equity of 8.02% and Windlas Biotech 12.23%.
Akums Drugs and Pharmaceuticals's share price is up 66.0% over one year and Windlas Biotech's is up 1.4%.
Akums Drugs and Pharmaceuticals reported revenue of ₹1,342 Cr and net profit of ₹115 Cr for Q2 FY27. Windlas Biotech reported revenue of ₹264 Cr and net profit of ₹18 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Life Sciences Tools and Services > Domestic contract manufacturers on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.